Key properties: Stimulates GH release from the pituitary (not the hypothalamus) Does not significantly raise cortisol or prolactin Short half-life (~2 hours) produces a sharp, pulsatile GH release Does not block somatostatin (the hormone that inhibits GH release) Selective for GH minimal effect on other hormones The selectivity is what makes ipamorelin the preferred GHRP for most protocols
Inside, you have a total of 10mg of peptide powder 5mg CJC-1295 and 5mg Ipamorelin
The pattern is consistent: dosing precision matters more than total volume, and subcutaneous administration outperforms intramuscular for systemic recovery applications
A proper specification includes the test, the method, and the acceptance limit
When used together, these medications offer dual appetite regulation with the potential for greater weight loss and metabolic improvements than either drug alone
However, dosing and timing should be managed by your provider